River Stone Biotech

Executive Summary

River Stone Biotech is a Danish synthetic biology company specializing in the enzymatic conversion and fermentation of high-value pharmaceutical ingredients, including prostaglandins and opioids such as buprenorphine, naloxone, and naltrexone. Founded in 2017 and currently at the pre-clinical stage, the company develops engineered microbial strains to produce these compounds, offering a scalable and sustainable alternative to traditional chemical synthesis and plant extraction. The technology aims to reduce production costs and environmental impact while ensuring consistent quality and supply. Although early-stage and with limited public details, River Stone Biotech operates in the expanding synthetic biology and API manufacturing space, with potential applications in pain management and regenerative medicine. The company is headquartered in Copenhagen, Denmark.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement60% success
• H1 2027Preclinical Proof-of-Concept Data for Opioid Fermentation50% success
• H2 2027Strategic Partnership with Pharmaceutical Company40% success